多替阿巴拉米片好用吗？

It is a compound preparation. Each tablet contains 50 mg of dolutegravir sodium (calculated as dolutegravir), 600 mg of abacavir sulfate (calculated as abacavir) and 300 mg of lamivudine. Clinically, it is suitable for the treatment of adults and adolescents over 12 years old infected with human immunodeficiency virus (HIV) (with a minimum weight of 40 kg).

In a phase I/II 48-week multicenter, open-label study (P1093/ING112578), the pharmacokinetic parameters, efficacy, tolerability, and safety of dolutegravir were evaluated in HIV-I-infected infants, children, and adolescents receiving the combination regimen. At week 24, 16 of 23 adolescents (aged 12 to 17 years) who received once-daily dolutegravir (35mgn=4; 50mgn=19) plus OBR achieved viral loads <50 copies/mL. In 20 of 23 children and adolescents (87%), the reduction in HIV-1 RNA from baseline at week 24 was greater than 1 log10 copies/mL or HIV-1 RNA <400 copies/mL. Four subjects experienced virological failure, but none had INI resistance at the time of virological failure. Taken together, the safety and effectiveness of doptabalamid tablets are good, and it is suitable for patients to choose to take.

Dolutegravir tablets are composed of three ingredients: DTG (DTG) + abacavir (ABC) + lamivudine (3TC). It is a compound treatment agent of integrase inhibitors and nucleoside drugs. Since the advent of the first anti-HIV treatment agent zidovudine (AZT) in 1987, which has brought hope to AIDS patients, more and more drugs have continued to appear, including efavirenz (EVF), Kaletra, tenofovir, and Ascent, until the newly released Tevicay in recent years. Anti-AIDS drugs have experienced the nucleoside With the development of different types of inhibitors, non-nucleoside inhibitors, protease inhibitors and integrase inhibitors in different periods, there are more and more types of drugs, the therapeutic effects are getting better and better, and the side effects are getting less and less. At present, the world has basically entered the era of integrase inhibitor drugs, and the optimization of multi-drug combination programs is constantly innovating. In 2016, GSK announced the launch of the integrase DTG (Tevicai) in China. This therapeutic agent has the advantages of small drug dosage, low resistance to drug resistance, and low probability of drug side effects. This time, doptabalamid tablets are based on DTG, an integrase inhibitor, as the core drug, coupled with a treatment plan of two backbone drugs, abacavir and lamivudine, and made into a single tablet treatment for promotion, making the core drug a great progress in HAART treatment. In addition, it can significantly reduce the medication burden of AIDS patients, thereby improving patients' medication compliance and effectively improving the patients' quality of life and work.